https://orcid.org/0000-0003-4520-5715
References
- Anantharamu T , SharmaS , GuptaAK , DahiyaN , SinghBrashier DB , SharmaAK. Naloxegol: first oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation. J. Pharmacol. Pharmacother.6(3), 188–192 (2020).
- Naloxegol (movantik) for opioid-induced constipation. JAMA315(2), 194–195 (2016).
- Holmberg M . Movantik by AstraZeneca Pharmaceuticals LP. Pharm. Times.81(2), 40 (2015).
- Pergolizzi JV Jr , RaffaRB , PappagalloMet al. Peripherally acting μ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy. Patient Prefer. Adherence.11, 107–119 (2017).
- Chey WD , WebsterL , SostekM , LappalainenJ , BarkerPN , TackJ. Naloxegol for opioid-induced constipation in patients with noncancer pain. N. Engl. J. Med.370(25), 2387–2396 (2014).
- AstraZeneca . MovantikTM (naloxegol tablets): US prescribing information (2014). http://www.astrazeneca-us.com/cgi-bin/az_pi.cgi?product=movantik&country=us&popup=no
- Webster L , CheyWD , TackJ , LappalainenJ , DivaU , SostekM. Randomised clinical trial: the long‐term safety and tolerability of naloxegol in patients with pain and opioid‐induced constipation. Aliment. Pharmacol. Ther.40, 771–779 (2014).
- Center for Drug Evaluation and Research . Table of substrates, inhibitors and inducers. US Food and Drug Administration, FDA (2020).
- Garnock-Jones KP . Naloxegol: a review of its use in patients with opioid-induced constipation. Drugs75(4), 419–425 (2015).
- Webster L , NalamachuS , MorlionBet al. Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double- blind, placebo-controlled phase 3 study. Pain159(5), 987–994 (2018).
- Crockett SD , GreerKB , HeidelbaughJJet al. American Gastroenterological Association Institute Guideline on the medical management of opioid-induced constipation. Gastroenterology156(1), 218–226 (2018).
- Rauck RL , SlatkinNE , StamblerN , IsraelRJ. Safety of oral methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain. J. Pain Res.12, 139–150 (2019).
- Webster L , MichnaE , KhanA , IsraelR , HarperJ. Long-term safety and efficacy of subcutaneous methylnaltrexone in patients with opioid-induced constipation and chronic noncancer pain: a Phase III, open-label trial. Pain Medicine.18, 1496–1504 (2017).
- Gudin J , FudinJ. Peripheral opioid receptor antagonists for opioid-induced constipation: a primer on pharmacokinetic variabilities with a focus on drug interactions. J. Pain Res.13, 447 (2020).